ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jan 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Tafamidis 61 mg capsule for treating transthyretin amyloid cardiomyopathy.

Funding status

Tafamidis 61 mg capsule is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

Tafamidis should be used in line with additional clinical criteria for initial and continuing prescriptions for patients with transthyretin amyloid cardiomyopathy.

MAF assistance does not apply to any other formulations or strengths of tafamidis.

Tafamidis for treating transthyretin amyloid cardiomyopathy (Updated 4 Jun 24) PES Tafamidis for treating transthyretin amyloid cardiomyopathy (Updated 4 Jun 24)